• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

为 RNA 治疗学铺平道路。

Paving the Road for RNA Therapeutics.

机构信息

Laboratory of Precision NanoMedicine, Tel Aviv University, Tel Aviv 69978, Israel; School of Molecular Cell Biology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel; Center for Nanoscience and Nanotechnology, and Tel Aviv University, Tel Aviv 69978, Israel; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel.

Laboratory of Precision NanoMedicine, Tel Aviv University, Tel Aviv 69978, Israel; School of Molecular Cell Biology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel; Center for Nanoscience and Nanotechnology, and Tel Aviv University, Tel Aviv 69978, Israel; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel.

出版信息

Trends Pharmacol Sci. 2020 Oct;41(10):755-775. doi: 10.1016/j.tips.2020.08.004. Epub 2020 Sep 3.

DOI:10.1016/j.tips.2020.08.004
PMID:32893005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7470715/
Abstract

Therapeutic RNA molecules possess high potential for treating medical conditions if they can successfully reach the target cell upon administration. However, unmodified RNA molecules are rapidly degraded and cleared from the circulation. In addition, their large size and negative charge complicates their passing through the cell membrane. The difficulty of RNA therapy, therefore, lies in the efficient intracellular delivery of intact RNA molecules to the tissue of interest without inducing adverse effects. Here, we outline the recent developments in therapeutic RNA delivery and discuss the wide potential in manipulating the function of cells with RNAs. The focus is not only on the variety of delivery strategies but also on the versatile nature of RNA and its wide applicability. This wide applicability is especially interesting when considering the modular nature of nucleic acids. An optimal delivery vehicle, therefore, can facilitate numerous clinical applications of RNA.

摘要

治疗性 RNA 分子如果能在给药后成功到达靶细胞,具有很高的治疗医疗状况的潜力。然而,未经修饰的 RNA 分子在体内会迅速降解并从循环中清除。此外,它们的体积大和带负电荷使得它们难以穿过细胞膜。因此,RNA 治疗的难点在于如何有效地将完整的 RNA 分子递送到靶组织而不引起不良反应。在这里,我们概述了治疗性 RNA 递送的最新进展,并讨论了用 RNA 来操纵细胞功能的广泛潜力。重点不仅在于各种递送策略,还在于 RNA 的多功能性及其广泛的适用性。当考虑到核酸的模块化性质时,这种广泛的适用性尤其有趣。因此,一个理想的递送载体可以促进 RNA 的许多临床应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/7470715/38c09f0d0912/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/7470715/bdc5f099988c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/7470715/38c09f0d0912/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/7470715/bdc5f099988c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/7470715/38c09f0d0912/gr2_lrg.jpg

相似文献

1
Paving the Road for RNA Therapeutics.为 RNA 治疗学铺平道路。
Trends Pharmacol Sci. 2020 Oct;41(10):755-775. doi: 10.1016/j.tips.2020.08.004. Epub 2020 Sep 3.
2
Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.靶向含核酸纳米颗粒的物理化学和生物学特性
Bioconjug Chem. 2007 Mar-Apr;18(2):456-68. doi: 10.1021/bc0603539. Epub 2007 Feb 28.
3
Recent advances of metal-based nanoparticles in nucleic acid delivery for therapeutic applications.金属基纳米颗粒在核酸治疗应用中的最新进展。
J Nanobiotechnology. 2022 Nov 24;20(1):501. doi: 10.1186/s12951-022-01650-z.
4
Delivery strategies of RNA therapeutics to leukocytes.RNA 治疗药物递送至白细胞的策略。
J Control Release. 2022 Feb;342:362-371. doi: 10.1016/j.jconrel.2022.01.016. Epub 2022 Jan 15.
5
Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge.RNAi 药物治疗传递中的复杂性:分析挑战。
Expert Opin Drug Deliv. 2014 Sep;11(9):1481-95. doi: 10.1517/17425247.2014.927439. Epub 2014 Jun 20.
6
Evaluating the breadth of nucleic acid-based payloads delivered in lipid nanoparticles to establish fundamental differences in development.评估脂质纳米粒中递送的基于核酸的有效载荷的广度,以确定在开发方面的根本差异。
Expert Opin Drug Deliv. 2024 Oct;21(10):1441-1461. doi: 10.1080/17425247.2024.2409142. Epub 2024 Oct 16.
7
Unleashing the potential of natural protein based nanoparticles for the delivery of therapeutic nucleic Acid: A comprehensive review.释放基于天然蛋白质的纳米颗粒在治疗性核酸递送方面的潜力:综述
Int J Pharm. 2025 Jan 25;669:125049. doi: 10.1016/j.ijpharm.2024.125049. Epub 2024 Dec 12.
8
Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery.用于组合核酸递送的癌症靶向纳米颗粒。
Adv Mater. 2020 Apr;32(13):e1901081. doi: 10.1002/adma.201901081. Epub 2019 Jun 20.
9
Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy.使用基于非共价肽的策略递送蛋白质和核酸。
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):537-47. doi: 10.1016/j.addr.2007.09.005. Epub 2007 Oct 25.
10
Strategies to deliver RNA by nanoparticles for therapeutic potential.纳米颗粒递送 RNA 的策略及其治疗潜力。
Mol Aspects Med. 2022 Feb;83:100991. doi: 10.1016/j.mam.2021.100991. Epub 2021 Aug 5.

引用本文的文献

1
Membrane-modified lipid nanoparticles for RNA delivery.用于RNA递送的膜修饰脂质纳米颗粒。
Mol Ther Methods Clin Dev. 2025 Jun 9;33(3):101505. doi: 10.1016/j.omtm.2025.101505. eCollection 2025 Sep 11.
2
On-Chip De Novo Production of mRNA Vaccine in Lipid Nanoparticles.脂质纳米颗粒中mRNA疫苗的片上从头生产
Small. 2025 Aug;21(32):e2500114. doi: 10.1002/smll.202500114. Epub 2025 Jun 23.
3
High-Resolution HPLC for Separating Peptide-Oligonucleotide Conjugates.用于分离肽 - 寡核苷酸缀合物的高分辨率高效液相色谱法。

本文引用的文献

1
Progress and challenges towards CRISPR/Cas clinical translation.CRISPR/Cas 临床转化的进展与挑战。
Adv Drug Deliv Rev. 2020;154-155:176-186. doi: 10.1016/j.addr.2020.07.004. Epub 2020 Jul 10.
2
RNA Therapy: Current Status and Future Potential.RNA疗法:现状与未来潜力
Chonnam Med J. 2020 May;56(2):87-93. doi: 10.4068/cmj.2020.56.2.87. Epub 2020 May 25.
3
Phosphorothioate modified oligonucleotide-protein interactions.硫代磷酸酯修饰的寡核苷酸-蛋白质相互作用。
ACS Omega. 2025 Apr 30;10(20):20578-20584. doi: 10.1021/acsomega.5c01308. eCollection 2025 May 27.
4
Differential Protein Precipitation-Based GalNAc-siRNA Sample Preparation with LC/MS Method Development Workflow in Plasma.基于差异蛋白质沉淀的GalNAc-siRNA血浆样本制备及液相色谱/质谱方法开发流程
Anal Chem. 2025 Jun 10;97(22):11388-11393. doi: 10.1021/acs.analchem.5c01587. Epub 2025 May 26.
5
The Fomivirsen, Patisiran, and Givosiran Odyssey: How the Success Stories May Pave the Way for Future Clinical Translation of Nucleic Acid Drugs.福米韦生、帕替拉韦和吉沃赛生的历程:成功案例如何为核酸药物未来的临床转化铺平道路。
BioDrugs. 2025 May;39(3):359-371. doi: 10.1007/s40259-025-00711-7. Epub 2025 Apr 5.
6
RNA-Based Therapies in Kidney Diseases.基于RNA的肾脏疾病治疗方法
J Inflamm Res. 2025 Mar 4;18:3143-3160. doi: 10.2147/JIR.S505252. eCollection 2025.
7
Advances in RNA-Based Therapeutics: Challenges and Innovations in RNA Delivery Systems.基于RNA的治疗学进展:RNA递送系统中的挑战与创新
Curr Issues Mol Biol. 2024 Dec 31;47(1):22. doi: 10.3390/cimb47010022.
8
RNA nanotherapeutics for hepatocellular carcinoma treatment.用于治疗肝细胞癌的RNA纳米疗法。
Theranostics. 2025 Jan 1;15(3):965-992. doi: 10.7150/thno.102964. eCollection 2025.
9
Enzyme-Responsive Nanoparachute for Targeted miRNA Delivery: A Protective Strategy Against Acute Liver and Kidney Injury.用于靶向递送微小RNA的酶响应性纳米降落伞:一种针对急性肝肾损伤的保护策略
Adv Sci (Weinh). 2025 Mar;12(10):e2411210. doi: 10.1002/advs.202411210. Epub 2024 Dec 24.
10
Widespread 3'UTR capped RNAs derive from G-rich regions in proximity to AGO2 binding sites.广泛存在的 3'UTR 加帽 RNA 来源于接近 AGO2 结合位点的富含 G 区域。
BMC Biol. 2024 Nov 7;22(1):254. doi: 10.1186/s12915-024-02032-7.
Nucleic Acids Res. 2020 Jun 4;48(10):5235-5253. doi: 10.1093/nar/gkaa299.
4
Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes.用于RNA治疗和白细胞免疫调节的靶向脂质纳米颗粒。
Adv Drug Deliv Rev. 2020;159:364-376. doi: 10.1016/j.addr.2020.04.002. Epub 2020 Apr 13.
5
Screening of efficient polymers for siRNA delivery in a library of hydrophobically modified polyethyleneimines.在疏水改性聚乙烯亚胺文库中筛选用于小干扰RNA递送的高效聚合物。
J Mater Chem B. 2016 Oct 21;4(39):6468-6474. doi: 10.1039/c6tb01929c. Epub 2016 Sep 28.
6
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.两项降低 LDL 胆固醇的依洛尤单抗 3 期临床试验。
N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18.
7
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives.用于递送mRNA的纳米药物:现状与未来展望。
Nanomaterials (Basel). 2020 Feb 20;10(2):364. doi: 10.3390/nano10020364.
8
A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes.用于将 RNA 递送至白细胞的脂质纳米颗粒的组合文库。
Adv Mater. 2020 Mar;32(12):e1906128. doi: 10.1002/adma.201906128. Epub 2020 Jan 30.
9
Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.体外基于细胞的 CRISPR/Cas9 基因组编辑用于治疗应用。
Biomaterials. 2020 Mar;234:119711. doi: 10.1016/j.biomaterials.2019.119711. Epub 2020 Jan 10.
10
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs.基于 RNA 的治疗学:从反义寡核苷酸到 miRNA。
Cells. 2020 Jan 7;9(1):137. doi: 10.3390/cells9010137.